Online inquiry

IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9322MR)

This product GTTS-WQ9322MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets HLA gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001242524.2;
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3113; 3108; 3111; 3117; 3123
UniProt ID Q30058; P28067; P28068; P06340; P13765; O19764; E1ACV6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9322MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9985MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA KD-247
GTTS-WQ692MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA A-1230717
GTTS-WQ5707MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ14118MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aNGF75
GTTS-WQ2893MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ13593MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA QAX-576
GTTS-WQ3493MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ5481MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDB-1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW